GLPwatch

Glutide for Ending Methamphetamine

NCT07204249 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests the effectiveness of a medication called Glutide in helping people with methamphetamine dependence enroll in a treatment study.

Status Not yet recruiting Approved but enrollment has not started.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 162 people Planned (estimated).
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2026-01 · est. completion 2030-02

What this study is testing ClinicalTrials.gov NCT07204249 ↗

Description as written by the study sponsor.

GEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-week treatment period, with a subsequent follow-up visit at week 20. This phase will evaluate the feasibility, acceptability, and preliminary efficacy of Wegovy for MeUD. The second phase will be a phase IIb randomized-controlled trial to determine the efficacy of Wegovy in treating MeUD. This trial will be similar to the pilot with randomization to Wegovy or placebo and blinding of group assignment. The trial will enroll 162 participants across two sites.

Treatments tested

Main thing measuredRatio of eligible to enrolled participants
SponsorSan Francisco Department of Public Health
Conditions studiedMethamphetamine-dependence
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07204249 ↗